Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
The Oncologist|June 2, 2018
A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and SarcomasRobert Meehan, Shivaani Kummar, Khanh Do, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 5, 2019
Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson's DiseaseMarisa Cressatti, Lamin Juwara, Julia M Galindez, et al.
Investigational New Drugs|August 16, 2017
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profileGiovanna Speranza, Larry Anderson, Alice P Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2011
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumorsShivaani Kummar, Mark Raffeld, Lamin Juwara, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2011
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomasShivaani Kummar, Martin E Gutierrez, Alice Chen, et al.
Breast Cancer Research and Treatment|February 5, 2026
Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudyAndréanne Leblanc, Ana-Alicia Beltran-Bless, Gregory R Pond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2017
Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis)Shivaani Kummar, Geraldine O'Sullivan Coyne, Khanh T Do, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2022
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part SarcomaJames Nguyen, Naoko Takebe, Shivaani Kummar, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2023
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumorsArjun Mittra, Geraldine H O' Sullivan Coyne, Jennifer Zlott, et al.
JCO Precision Oncology|July 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid TumorsGeraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar, et al.
Pageof 3